Explore
0
0
Following
0
0
Notifications
0
0
Messages
0
0
History
0
0
Favorites
0
0
Rewards
0
0
About
Contact Us
Agreement
Privacy
©
2023 32Plus CO.,LTD.
History
Clear
Try to search for users or keywords
View results for "
"
Register
Sign In
CASI-Pharmaceuticals-凯信远达
PT
Lv
2
2023-5-11 16:31
· contributed a column
From China
Follow
Column
CASI制药CNCT19细胞注射液获美国FDA孤儿药资格认定 正式开启全球化征程
2022年1月18日,CASI制药宣布,其合作伙伴合源生物旗下靶向CD19 CAR-T药物CNCT19细胞注射液获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定(Orphan Drug Designation, ODD),用于治疗急性淋巴细胞白血病(Acute Lymphoblastic Leukemia, ALL)。
1,304
4
Repost
4
95
Please
Sign In
to post a comment~
Loading...
CASI-Pharmaceuticals-凯信远达
CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company.
Followers
28
Feed
10
View Zone